Cargando…
Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin
Simvastatin (STT), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is widely prescribed for dyslipidemia, whereas fluoxetine (FLX) is the first-choice drug for the treatment of depression and anxiety. A recent report suggests that selective serotonin reuptake inhibitors can interact wit...
Autores principales: | Al-Asmari, Abdulrahman K, Ullah, Zabih, Al Masoudi, Aqeel Salman, Ahmad, Ishtiaque |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395284/ https://www.ncbi.nlm.nih.gov/pubmed/28442937 http://dx.doi.org/10.2147/JEP.S128696 |
Ejemplares similares
-
Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression
por: Santos, Tainaê, et al.
Publicado: (2012) -
Simvastatin Attenuates Contrast-Induced Nephropathy through Modulation of Oxidative Stress, Proinflammatory Myeloperoxidase, and Nitric Oxide
por: Al-Otaibi, Ketab E., et al.
Publicado: (2012) -
Simvastatin-Loaded Lipid Emulsion Nanoparticles: Characterizations
and Applications
por: Ullah, Faiz, et al.
Publicado: (2022) -
Antiapoptotic Effect of Simvastatin Ameliorates Myocardial Ischemia/Reperfusion Injury
por: Hadi, Najah R., et al.
Publicado: (2013) -
Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats
por: Al-Rasheed, Nawal M., et al.
Publicado: (2017)